Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cardiology and Therapy
Published in: Cardiology and Therapy 2/2017

Open Access 01-12-2017 | Review

Management and Prevention of Saphenous Vein Graft Failure: A Review

Authors: Peter McKavanagh, Bobby Yanagawa, George Zawadowski, Asim Cheema

Published in: Cardiology and Therapy | Issue 2/2017

Login to get access

Abstract

Coronary artery bypass grafting (CABG) remains a vital treatment for patients with multivessel coronary artery disease (CAD), especially diabetics. The long-term benefit of the internal thoracic artery graft is well established and remains the gold standard for revascularization of severe CAD. It is not always possible to achieve complete revascularization through arterial grafts, necessitating the use of saphenous vein grafts (SVG). Unfortunately, SVGs do not have the same longevity, and their failure is associated with significant adverse cardiac outcomes and mortality. This paper reviews the pathogenesis of SVG failure, highlighting the difference between early, intermediate, and late failure. It also addresses the different surgical techniques that affect the incidence of SVG failure, as well as the medical and percutaneous prevention and treatment options in contemporary practice.
Literature
1.
Yusuf S, Zucker D, Peduzzi P, Fisher LD, Takaro T, Kennedy JW, Davis K, Killip T, Passamani E, Norris R. Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet. 1994;344:563–70.PubMedCrossRef
2.
Davis KB, Chaitman B, Ryan T, Bittner V, Kennedy JW. Comparison of 15-year survival for men and women after initial medical or surgical treatment for coronary artery disease. J Am Coll Cardiol. 1995;25:1000–9.PubMedCrossRef
3.
Banning AP, Westaby S, Morice M-C, Kappetein AP, Mohr FW, Berti S, et al. Diabetic and nondiabetic patients with left main and/or 3-vessel coronary artery disease: comparison of outcomes with cardiac surgery and paclitaxel-eluting stents. J Am Coll Cardiol. 2010;55:1067–75.PubMedCrossRef
4.
Dangas GD, Farkouh ME, Sleeper LA, Yang M, Schoos MM, Macaya C, Abizaid A, Buller CE, Devlin G, Rodriguez AE, Lansky AJ, Siami FS, Domanski M, Fuster V, FREEDOM Investigators. Long-term outcome of PCI versus CABG in insulin and non-insulin-treated diabetic patients: results from the FREEDOM trial. J Am Coll Cardiol. 2014;64(12):1189–97.PubMedCrossRef
5.
BARI 2D Study Group, Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF, MacGregor JM, Orchard TJ, Chaitman BR, Genuth SM, Goldberg SH, Hlatky MA, Jones TL, Molitch ME, Nesto RW, Sako EY, Sobel BE. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009;360(24):2503–15.CrossRef
6.
Roger VL, Go AS, Lloyd-Jones DM, et al. Executive summary: heart disease and stroke statistics—2012 update: a report from the American Heart Association. Circulation. 2012;125:188–97.PubMedCrossRef
7.
Greenland P, Knoll MD, Stamler J, et al. Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA. 2003;290:891–7.PubMedCrossRef
8.
Campeau L, Enjalbert M, Lespérance J, et al. The relation of risk factors to the development of atherosclerosis in saphenous-vein bypass grafts and the progression of disease in the native circulation. A study 10 years after aortocoronary bypass surgery. N Engl J Med. 1984;311:1329–32.PubMedCrossRef
9.
Loop FD, Lytle BW, Cosgrove DM, Stewart RW, Goormastic M, Williams GW, Golding LA, Gill CC, Taylor PC, Sheldon WC, et al. Influence of the internal-mammary-artery graft on 10-year survival and other cardiac events. N Engl J Med. 1986;314(1):1–6.PubMedCrossRef
10.
Fitzgibbon GM, Kafka HP, Leach AJ, Keon WJ, Hooper GD, Burton JR. Coronary bypass graft fate and patient outcome: angiographic follow-up of 5065 grafts related to survival and reoperation in 1388 patients during 25 years. J Am Coll Cardiol. 1996;28:616–26.PubMedCrossRef
11.
Alexander JH, Hafley G, Harrington RA, Peterson ED, Ferguson TB Jr, Lorenz TJ, Goyal A, Gibson M, Mack MJ, Gennevois D, Califf RM, Kouchoukos NT, PREVENT IV Investigators. Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. JAMA. 2005;294(19):2446–54.PubMedCrossRef
12.
Bourassa MG, Fisher LD, Campeau L, Gillespie MJ, McConney M, Lesperance J. Long-term fate of bypass grafts: the coronary artery surgery study (CASS) and Montreal Heart Institute experiences. Circulation. 1985;72:V71–8.PubMed
13.
Campeau L, Lesperance J, Hermann J, Corbara F, Grondin CM, Bourassa MG. Loss of the improvement of angina between 1 and 7 years after aortocoronary bypass surgery: correlations with changes in vein grafts and in coronary arteries. Circulation. 1979;60:1–5.PubMedCrossRef
14.
Taggart DP, Altman DG, Gray AM, Lees B, Nugara F, Yu LM, Campbell H, Flather M, ART Investigators. Randomized trial to compare bilateral vs. single internal mammary coronary artery bypass grafting: 1-year results of the Arterial Revascularisation Trial (ART). Eur Heart J. 2010;31(20):2470–81.PubMedCrossRef
15.
Muneretto C, Bisleri G, Negri A, Manfredi J, Metra M, Nodari S, Culot L, Dei Cas L. Total arterial myocardial revascularization with composite grafts improves results of coronary surgery in elderly: a prospective randomized comparison with conventional coronary artery bypass surgery. Circulation. 2003;108 Suppl 1:II29–33.PubMed
16.
Locker C, Schaff HV, Dearani JA, Joyce LD, Park SJ, Burkhart HM, Suri RM, Greason KL, Stulak JM, Li Z, Daly RC. Multiple arterial grafts improve late survival of patients undergoing coronary artery bypass graft surgery: analysis of 8622 patients with multivessel disease. Circulation. 2012;126(9):1023–30.PubMedCrossRef
17.
Takagi H, Goto SN, Watanabe T, Mizuno Y, Kawai N, Umemoto T. A meta-analysis of adjusted hazard ratios from 20 observational studies of bilateral versus single internal thoracic artery coronary artery bypass grafting. J Thorac Cardiovasc Surg. 2014;148(4):1282–90.PubMedCrossRef
18.
Weiss AJ, Zhao S, Tian DH, Taggart DP, Yan TD. A meta-analysis comparing bilateral internal mammary artery with left internal mammary artery for coronary artery bypass grafting. Ann Cardiothorac Surg. 2013;2(4):390–400.PubMedPubMedCentral
19.
Deo SV, Altarabsheh SE, Shah IK, Cho YH, McGraw M, Sarayyepoglu B, Medalion B, Markowitz AH, Park SJ. Are two really always better than one? Results, concerns and controversies in the use of bilateral internal thoracic arteries for coronary artery bypass grafting in the elderly: a systematic review and meta-analysis. Int J Surg. 2015;16:163–70.PubMedCrossRef
20.
Fleissner F, Engelke H, Rojas-Hernandez S, Ismail I, Stiefel P, Cebotari S, Haverich A, Shrestha M, Martens A. Long-term follow-up of total arterial revascularization with left internal thoracic artery and radial artery T-grafts: survival, cardiac morbidity and quality of life. Eur J Cardiothorac Surg. 2015;49(4):1195–200.PubMedCrossRef
21.
Deb S, Cohen EA, Singh SK, Une D, Laupacis A, Fremes SE, RAPS Investigators. Radial artery and saphenous vein patency more than 5 years after coronary artery bypass surgery: results from RAPS (Radial Artery Patency Study). J Am Coll Cardiol. 2012;60(1):28–35.PubMedCrossRef
22.
ElBardissi AW, Aranki SF, Sheng S, O’Brien SM, Greenberg CC, Gammie JS. Trends in isolated coronary artery bypass grafting: an analysis of the Society of Thoracic Surgeons adult cardiac surgery database. J Thorac Cardiovasc Surg. 2012;143(2):273–81.PubMedCrossRef
23.
Taggart DP, Altman DG, Gray AM, Lees B, Gerry S, Benedetto U, Flather M, ART Investigators. Randomized trial of bilateral versus single internal-thoracic-artery grafts. N Engl J Med. 2016;375(26):2540–9.PubMedCrossRef
24.
Lichtenwalter C, de Lemos JA, Roesle M, et al. Clinical presentation and angiographic characteristics of saphenous vein graft failure after stenting: insights from the SOS (stenting of saphenous vein grafts) trial. JACC Cardiovasc Interv. 2009;2:855–60.PubMedCrossRef
25.
Motwani JG, Topol EJ. Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. Circulation. 1998;97(9):916–31.PubMedCrossRef
26.
McGeachie JK, Meagher S, Prendergast FJ. Vein-to-artery grafts: the long-term development of neo-intimal hyperplasia and its relationship to vasa vasorum and sympathetic innervation. Aust N Z J Surg. 1989;59:59–65.PubMedCrossRef
27.
Angelini GD, Passani SL, Breckenridge IM, et al. Nature and pressure dependence of damage induced by distension of human saphenous vein coronary artery bypass grafts. Cardiovasc Res. 1987;21:902–7.PubMedCrossRef
28.
Kennedy JH, Lever MJ, Addis BJ, et al. Changes in vein interstitium following distension for aortocoronary bypass. J Cardiovasc Surg. 1989;30:992–5.
29.
30.
Ishiwata S, Tukada T, Nakanishi S, et al. Postangioplasty restenosis: platelet activation and the coagulation-fibrinolysis system as possible factors in the pathogenesis of restenosis. Am Heart J. 1997;133:387–92.PubMedCrossRef
31.
32.
Chesebro JH, Fuster V, Elveback LR, Clements IP, Smith HC, Holmes DR Jr, Bardsley WT, Pluth JR, Wallace RB, Puga FJ, Orszulak TA, Piehler JM, Danielson GK, Schaff HV, Frye RL. Effect of dipyridamole and aspirin on late vein-graft patency after coronary bypass operations. N Engl J Med. 1984;310:209–14.PubMedCrossRef
33.
Allaire E, Clowes AW. Endothelial cell injury in cardiovascular surgery: the intimal hyperplastic response. Ann Thorac Surg. 1997;63(2):582–91.PubMedCrossRef
34.
35.
Schwartz SM, Deblois D, O’Brien ER. The intima. Soil for atherosclerosis and restenosis. Circ Res. 1995;77:445–65.PubMedCrossRef
36.
Zhang L, Peppel K, Brian L, Chien L, Freedman NJ. Vein graft neointimal hyperplasia is exacerbated by tumor necrosis factor receptor-1 signaling in graft-intrinsic cells. Arterioscler Thromb Vasc Biol. 2004;24:2277–83.PubMedCrossRef
37.
Stary HC, Blankenhorn DH, Chandler AB, Glagov S, Insull W Jr, Richardson M, Rosenfeld ME, Schaffer SA, Schwartz CJ, Wagner WD. A definition of the intima of human arteries and of its atherosclerosis-prone regions. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation. 1992;85:391–405.PubMedCrossRef
38.
Hermiller JB, Tenaglia AN, Kisslo KB, et al. In vivo validation of compensatory enlargement of atherosclerotic coronary arteries. Am J Cardiol. 1993;71:665–8.PubMedCrossRef
39.
Cameron AA, Green GE, Brogno DA, Thornton J. Internal thoracic artery grafts: 20-year clinical follow-up. J Am Coll Cardiol. 1995;25:188–92.PubMedCrossRef
40.
Hong YJ, Jeong MH, Ahn Y, Kang JC, Mintz GS, Kim SW, et al. Impact of lesion location on intravascular ultrasound findings and short-term and five-year long-term clinical outcome after percutaneous coronary intervention for saphenous vein graft lesions. Int J Cardiol. 2013;167(1):29–33.PubMedCrossRef
41.
Sano K, Mintz GS, Carlier SG, Fujii K, Yasuda T, Kimura M, et al. Intravascular ultrasonic differences between aorto-ostial and shaft narrowing in saphenous veins used as aortocoronary bypass grafts. Am J Cardiol. 2006;97(10):1463–6.PubMedCrossRef
42.
Kennedy JW, Kaiser GC, Fisher LD, et al. Multivariatediscriminant analysis of the clinical and angiographic predictors of operative mortality from the Collaborative Study in Coronary Artery Surgery (CASS). J Thorac Cardiovasc Surg. 1980;80:876–87.PubMed
43.
Yanagawa B, Algarni KD, Singh SK, et al. Clinical, biochemical, and genetic predictors of coronary arterybypass graft failure. J Thorac Cardiovasc Surg. 2014;148:515–20.PubMedCrossRef
44.
45.
Mehta RH, Honeycutt E, Shaw LK, Sketch MH Jr. Clinical characteristics associated with poor long-term survival among patients with diabetes mellitus undergoing saphenous vein graft interventions. Am Heart J. 2008;156(4):728–35.PubMedCrossRef
46.
Faulkner SL, Fisher RD, Conkle DM, Page DL, Bender HW Jr. Effect of blood flow rate on subendothelial proliferation in venous autografts used as arterial substitutes. Circulation. 1975;52(2 Suppl):I163–72.PubMed
47.
Sabik JF III, Blackstone EH. Coronary artery bypass graft patency and competitive flow. J Am Coll Cardiol. 2008;51:126–8.PubMedCrossRef
48.
Sabik JF III, Lytle BW, Blackstone EH, Khan M, Houghtaling PL, Cosgrove DM. Does competitive flow reduce internal thoracic artery graft patency? Ann Thorac Surg. 2003;76:1490–7.PubMedCrossRef
49.
LoGerfo FW, Corson JD. Mannick JA Improved results with femoropopliteal vein grafts for limb salvage. Arch Surg. 1977;112(5):567–70.PubMedCrossRef
50.
Souza DS, Dashwood MR, Tsui JC, Filbey D, Bodin L, Johansson B, Borowiec J. Improved patency in vein grafts harvested with surrounding tissue: results of a randomized study using three harvesting techniques. Ann Thorac Surg. 2002;73(4):1189–95.PubMedCrossRef
51.
Souza DS, Johansson B, Bojö L, Karlsson R, Geijer H, Filbey D, Bodin L, Arbeus M, Dashwood MR. Harvesting the saphenous vein with surrounding tissue for CABG provides long-term graft patency comparable to the left internal thoracic artery: results of a randomized longitudinal trial. J Thorac Cardiovasc Surg. 2006;132(2):373–8.PubMedCrossRef
52.
Verma S, Lovren F, Pan Y, Yanagawa B, Deb S, Karkhanis R, Quan A, Teoh H, Feder-Elituv R, Moussa F, Souza DS, Fremes SE. Pedicled no-touch saphenous vein graft harvest limits vascular smooth muscle cell activation: the PATENT saphenous vein graft study. Eur J Cardiothorac Surg. 2014;45(4):717–25.PubMedCrossRef
53.
Samano N, Geijer H, Liden M, Fremes S, Bodin L, Souza D. The no-touch saphenous vein for coronary artery bypass grafting maintains a patency, after 16 years, comparable to the left internal thoracic artery: a randomized trial. J Thorac Cardiovasc Surg. 2015;150(4):880–8.PubMedCrossRef
54.
Nathoe HM, van Dijk D, Jansen EW, Octopus Study Group, et al. A comparison of on-pump and off-pump coronary bypass surgery in low-risk patients. N Engl J Med. 2003;348:394–402.PubMedCrossRef
55.
Puskas JD, Williams WH, Mahoney EM, et al. Off-pump vs conventional coronary artery bypass grafting: early and 1-year graft patency, cost, and quality-of-life outcomes: a randomized trial. JAMA. 2004;291:1841–9.PubMedCrossRef
56.
Straka Z, Widimsky P, Jirasek K, Stros P, Votava J, Vanek T, Brucek P, Kolesar M, Spacek R. Off-pump versus on-pump coronary surgery: final results from a prospective randomized study PRAGUE-4. Ann Thorac Surg. 2004;77(3):789–93.PubMedCrossRef
57.
Widimsky P, Straka Z, Stros P, et al. One-year coronary bypass graft patency: a randomized comparison between off-pump and on-pump surgery angiographic results of the PRAGUE-4 trial. Circulation. 2004;110:3418–23.PubMedCrossRef
58.
Hattler B, Messenger JC, Shroyer AL, Collins JF, Haugen SJ, Garcia JA, Baltz JH, Cleveland JC Jr, Novitzky D, Grover FL, Veterans Affairs Randomized On/Off Bypass (ROOBY) Study Group. Off-Pump coronary artery bypass surgery is associated with worse arterial and saphenous vein graft patency and less effective revascularization: results from the Veterans Affairs Randomized On/Off Bypass (ROOBY) trial. Circulation. 2012;125(23):2827–35.PubMedCrossRef
59.
Puskas JD, Williams WH, O’Donnell R, Patterson RE, Sigman SR, Smith AS, Baio KT, Kilgo PD, Guyton RA. Off-pump and on-pump coronary artery bypass grafting are associated with similar graft patency, myocardial ischemia, and freedom from reintervention: long-term follow-up of a randomized trial. Ann Thorac Surg. 2011;91(6):1836–42.PubMedCrossRef
60.
Sousa Uva M, Cavaco S, Oliveira AG, Matias F, Silva C, Mesquita A, Aguiar P, Bau J, Pedro A, Magalhães MP. Early graft patency after off-pump and on-pump coronary bypass surgery: a prospective randomized study. Eur Heart J. 2010;31(20):2492–9.PubMedCrossRef
61.
Takagi H, Matsui M, Umemoto T. Lower graft patency after off-pump than on-pump coronary artery bypass grafting: an updated meta-analysis of randomized trials. J Thorac Cardiovasc Surg. 2010;140(3):e45–7.PubMedCrossRef
62.
Zhang B, Zhou J, Li H, Liu Z, Chen A, Zhao Q. Comparison of graft patency between off-pump and on-pump coronary artery bypass grafting: an updated meta-analysis. Ann Thorac Surg. 2014;97(4):1335–41.PubMedCrossRef
63.
Flemma RJ, Johnson WD, Lepley D. Triple aorto-coronary vein bypass for coronary insufficiency. Arch Surg. 1971;103:82–3.PubMedCrossRef
64.
Bartley TD, Bigelow JC, Page US. Aortocoronary bypass grafting with multiple sequential anastomoses to a single vein. Arch Surg. 1972;105:915–7.PubMedCrossRef
65.
Sewell WH, Sewell KV. Technique for the coronary snake graft operation. Ann Thorac Surg. 1976;22:58–65.PubMedCrossRef
66.
Grondin CM, Limet R. Sequential anastomoses in coronary grafting: technical aspects and early and late angiographic results. Ann Thorac Surg. 1977;23:1–8.PubMedCrossRef
67.
Sauvage LR, Wu HD, Kowalsky TE, Davis CC, Smith JC, Rittenhouse EA, et al. Healing basis and surgical techniques for complete revascularization of the left ventricle using only the internal mammary arteries. Ann Thorac Surg. 1986;42:449–65.PubMedCrossRef
68.
Mehta RH, Ferguson TB, Lopes RD, Hafley GE, Mack MJ, Kouchoukos NT, Gibson CM, Harrington RA, Califf RM, Peterson ED, Alexander JH. Saphenous vein grafts with multiple versus single distal targets in patients undergoing coronary artery bypass surgery: one-year graft failure and five-year outcomes from the Project of Ex-vivo Vein Graft Engineering via Transfection (PREVENT) IV Trial. Circulation. 2011;124:280–8.PubMedPubMedCentralCrossRef
69.
Christenson JT, Simonet F, Schmuziger M. Sequential vein bypass grafting: tactics and long-term results. Cardiovasc Surg. 1998;6:389–97.PubMedCrossRef
70.
Oz BS, Iyem H, Akay HT, Bolcal C, Yokusoglu M, Kuralay E, Demirkilic U, Tatar H. Mid-term angiographic comparison of sequential and individual anatomosis techniques for diagonal artery. J Card Surg. 2006;21:471–4.PubMedCrossRef
71.
Zilla P, Human P, Wolf M, Lichtenberg W, Nasser R, Bezuidenhout D, Samodien N, Schmidt C, Franz T. Constrictive external nitinol meshes inhibit vein graft intimal hyperplasia in non-human primates. J Thorac Cardiovasc Surg. 2008;136:717–25.PubMedCrossRef
72.
Moodley L, Franz T, Human P, Wolf MF, Bezuidenhout D, Scherman J, Zilla P. Protective constriction of coronary vein grafts with knitted nitinol. Eur J Cardiothorac Surg. 2013;44:64–71.PubMedPubMedCentralCrossRef
73.
Genoni M, Odavic D, Loblein H, Dzemali O. Use of the eSVS mesh: external vein support does not negatively impact early graft patency. Innovations (Philadelphia, Pa). 2013;8:211–4.CrossRef
74.
Klima U, Elsebay AA, Gantri MR, Bangardt J, Miller G, Emery RW. Computerized tomographic angiography in patients having eSVS mesh(R) supported coronary saphenous vein grafts: intermediate term results. J Cardiothorac Surg. 2014;9:138.PubMedCrossRef
75.
Inderbitzin DT, Bremerich J, Matt P, Grapow MT, Eckstein FS, Reuthebuch O. One-year patency control and risk analysis of eSVS®-mesh-supported coronary saphenous vein grafts. J Cardiothorac Surg. 2015;10:108.PubMedPubMedCentralCrossRef
76.
Nilsson T, Lagerqvist B, Tornvall P. Coronary angiography of patients with a previous coronary artery by-pass operation is associated with a three times increased risk for neurological complications. A report from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Scand Cardiovasc J. 2009;43(6):374–9.PubMedCrossRef
77.
Anders K, Baum U, Schmid M, Ropers D, Schmid A, Pohle K, Daniel WG, Bautz W, Achenbach S. Coronary artery bypass graft (CABG) patency: assessment with high-resolution submillimeter 16-slice multidetector-row computed tomography (MDCT) versus coronary angiography. Eur J Radiol. 2006;57(3):336–44.PubMedCrossRef
78.
Achenbach S, Moshage W, Ropers D, Nossen J, Bachmann K. Noninvasive, three-dimensional visualization of coronary artery bypass grafts by electron beam tomography. Am J Cardiol. 1997;79:856e861.75.CrossRef
79.
Ropers D, Ulzheimer S, Wenkel E, et al. Investigation of aortocoronary artery bypass grafts by multislice spiral computed tomography with electrocardiographic-gated image reconstruction. Am J Cardiol. 2001;88:792e795.
80.
Enzweiler CN, Wiese TH, Petersein J, et al. Diameter changes of occluded venous coronary artery bypass grafts in electron beam tomography: preliminary findings. Eur J Cardiothorac Surg. 2003;23:347e353.CrossRef
81.
Hamon M, Lepage O, Malagutti P, Riddell JW, Morello R, Agostini D, et al. Diagnostic performance of 16- and 64-section spiral CT for coronary artery bypass graft assessment: meta-analysis. Radiology. 2008;247(3):679–86.PubMedCrossRef
82.
Taylor AJ, Cerqueira M, Hodgson JM, Mark D, Min J, O’Gara P, et al. ACCF/SCCT/ACR/AHA/ASE/ASNC/NASCI/SCAI/SCMR 2010 Appropriate Use Criteria for Cardiac Computed Tomography. A Report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, the Society of Cardiovascular Computed Tomography, the American College of Radiology, the American Heart Association, the American Society of Echocardiography, the American Society of Nuclear Cardiology, the North American Society for Cardiovascular Imaging, the Society for Cardiovascular Angiog. Circulation. 2010;122(21):e525–55.PubMedCrossRef
83.
von Kiedrowski H, Wiemer M, Franzke K, Preuss R, Vaske B, Butz T. Non-invasive coronary angiography: the clinical value of multi-slice computed tomography in the assessment of patients with prior coronary bypass surgery: evaluating grafts and native vessels. Int J Cardiovasc Imaging. 2009;25(2):161–70.CrossRef
84.
Englberger L, Streich M, Tevaearai H, Carrel TP. Different anticoagulation strategies in off-pump coronary artery bypass operations: a European survey. Interact Cardiovasc Thorac Surg. 2008;7:378–82.PubMedCrossRef
85.
Pantely GA, Goodnight SH Jr, Rahimtoola SH, et al. Failure of antiplatelet and anticoagulant therapy to improve patency of grafts after coronary-artery bypass: a controlled, randomized study. N Engl J Med. 1979;301:962–6.PubMedCrossRef
86.
McEnany MT, Salzman EW, Mundth ED, DeSanctis RW, Harthorne JW, Weintraub RM, Gates S, Austen WG. The effect of antithrombotic therapy on patency rates of saphenous vein coronary artery bypass grafts. J Thorac Cardiovasc Surg. 1982;83(1):81–9.PubMed
87.
Chesebro JH, Clements IP, Fuster V, Elveback LR, Smith HC, Bardsley WT, Frye RL, Holmes DR Jr, Vlietstra RE, Pluth JR, Wallace RB, Puga FJ, Orszulak TA, Piehler JM, Schaff HV, Danielson GK. A platelet inhibitor-drug trial in coronary–artery bypass operations: benefit of perioperative dipyridamole and aspirin therapy on early postoperative vein-graft patency. N Engl J Med. 1982;307:73–8.PubMedCrossRef
88.
Goldman S, Copeland J, Moritz T, et al. Improvement in early saphenous vein graft patency after coronary artery bypass surgery with antiplatelet therapy: results of a Veterans Administration Cooperative Study. Circulation. 1988;77:1324–32.PubMedCrossRef
89.
Bybee KA, Powell BD, Valeti U, et al. Preoperative aspirin therapy is associated with improved postoperative outcomes in patients undergoing coronary artery bypass grafting. Circulation. 2005;112:I286–92.PubMed
90.
Mangano DT, Multicenter Study of Perioperative Ischemia Research Group. Aspirin and mortality from coronary bypass surgery. N Engl J Med. 2002;347:1309–17.PubMedCrossRef
91.
Dacey LJ, Munoz JJ, Johnson ER, et al. Effect of preoperative aspirin use on mortality in coronary artery bypass grafting patients. Ann Thorac Surg. 2000;70:1986–90.PubMedCrossRef
92.
Wijns W, Kolh P, Danchin N, et al. Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2010;31:2501–55.PubMedCrossRef
93.
Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, Society of Cardiovascular Anesthesiologists, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2011;58:e123–210.PubMedCrossRef
94.
Fox KA, Anderson FA Jr, Dabbous OH, Steg PG, López-Sendón J, Van de Werf F, Budaj A, Gurfinkel EP, Goodman SG, Brieger D, GRACE investigators. Intervention in acute coronary syndromes: do patients undergo intervention on the basis of their risk characteristics? The Global Registry of Acute Coronary Events (GRACE). Heart. 2007;93(2):177–82.PubMedCrossRef
95.
Ebrahimi R, Dyke C, Mehran R, et al. Outcomes following pre-operative clopidogrel administration in patients with acute coronary syndromes undergoing coronary artery bypass surgery: the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. J Am Coll Cardiol. 2009;53:1965–72.PubMedCrossRef
96.
Biancari F, Airaksinen KE, Lip GY. Benefits and risks of using clopidogrel before coronary artery bypass surgery: systematic review and meta-analysis of randomized trials and observational studies. J Thorac Cardiovasc Surg. 2012;143(3):665–75.PubMedCrossRef
97.
Dunning J, Versteegh M, Fabbri A, Pavie A, Kolh P, Lockowandt U, Nashef SA. Guideline on antiplatelet and anticoagulation management in cardiac surgery. Eur J Cardiothorac Surg. 2008;34:73–92.PubMedCrossRef
98.
Eagle KA, Guyton RA, Davidoff R, Edwards FH, Ewy GA, Gardner TJ, Hart JC, Herrmann HC, Hillis LD, Hutter AM, et al. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). Circulation. 2004;110:e340–437.PubMedCrossRef
99.
Fitchett D, Eikelboom J, Fremes S, Mazer D, Singh S, Bittira B, et al. Dual antiplatelet therapy in patients requiring urgent coronary artery bypass grafting surgery: a position statement of the Canadian Cardiovascular Society. Can J Cardiol. 2009;25:683–9.PubMedPubMedCentralCrossRef
100.
Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494–502.PubMedCrossRef
101.
Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel with acute coronary syndromes. N Engl J Med. 2007;357:2001–15.PubMedCrossRef
102.
Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045–57.PubMedCrossRef
103.
Jneid H, Anderson JL, Wright RS, Adams CD, Bridges CR, Casey DE Jr, et al. ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2012;60:645–81.PubMedCrossRef
104.
Tanguay JF, Bell AD, Ackman ML, Bauer RD, Cartier R, Chan WS, et al. Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy. Can J Cardiol. 2013;29:1334–45.PubMedCrossRef
105.
Sibbald M, Yan AT, Huang W, Fox KA, Gore JM, Steg PG, Eagle KA, Brieger D, Montalescot G, Goodman SG. Association between smoking, outcomes, and early clopidogrel use in patients with acute coronary syndrome: insights from the Global Registry of Acute Coronary Events. Am Heart J. 2010;160(5):855–61.PubMedCrossRef
106.
Fox KA, Eagle KA, Gore JM, Steg PG, Anderson FA, GRACE and GRACE2 Investigators. The global registry of acute coronary events, 1999 to 2009—GRACE. Heart. 2010;96(14):1095–101.PubMedCrossRef
107.
Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2011;32:2999–3054.PubMedCrossRef
108.
Kulik A, Chan V, Ruel M. Antiplatelet therapy and coronary artery bypass graft surgery: perioperative safety and efficacy. Expert Opin Drug Saf. 2009;8(2):169–82.PubMedCrossRef
109.
Krimly A, Yan RT, Yan AT, DeYoung JP, Gallo R, Steg G, et al. Use of clopidogrel post-coronary artery bypass surgery in canadian patients with acute coronary syndromes. Can J Cardiol. 2011;27:711–5.PubMedCrossRef
110.
Rao RV, Goodman SG, Yan RT, Spencer FA, Fox KA, DeYoung JP, et al. Temporal trends and patterns of early clopidogrel use across the spectrum of acute coronary syndromes. Am Heart J. 2009;157:642–50.PubMedCrossRef
111.
Gao C, Ren C, Li D, Li L. Clopidogrel and aspirin versus clopidogrel alone on graft patency after coronary artery bypass grafting. Ann Thorac Surg. 2009;88:59–62.PubMedCrossRef
112.
Sun JC, et al. Randomized trial of aspirin and clopidogrel versus aspirin alone for the prevention of coronary artery bypass graft occlusion: the Preoperative Aspirin and Postoperative Antiplatelets in Coronary Artery Bypass Grafting study. Am Heart J. 2010;160:1178–84.PubMedCrossRef
113.
Gao G, Zheng Z, Pi Y, Lu B, Lu J, Hu S. Aspirin plus clopidogrel therapy increases early venous graft patency after coronary artery bypass surgery a single-center, randomized, controlled trial. J Am Coll Cardiol. 2010;56(20):1639–43.PubMedCrossRef
114.
Kulik A, Le May MR, Voisine P, Tardif JC, Delarochelliere R, Naidoo S, Wells GA, Mesana TG, Ruel M. Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the Clopidogrel After Surgery For Coronary Artery Disease (CASCADE) Trial. Circulation. 2010;122:2680–7.PubMedCrossRef
115.
Mannacio VA, Di Tommaso L, Antignan A, De Amicis V, Vosa C. Aspirin plus clopidogrel for optimal platelet inhibition following off-pump coronary artery bypass surgery: results from the CRYSSA (prevention of Coronary arteRY bypaSS occlusion After off-pump procedures) randomised study. Heart. 2012;98(23):1710–5.PubMedCrossRef
116.
Rafiq S, Johansson P, Kofoed K, et al. Thrombelastographic hypercoagulability and antiplatelet therapy after coronary artery bypass surgery (TEG-CABG trial): a randomized controlled trial. Platelets. 2017;22:1–8.
117.
Kulik A, Ruel M, Jneid H, et al. Secondary prevention after coronary artery bypass surgery—a scientific statement from the American Heart Association. Circulation. 2015;131:927–64.PubMedCrossRef
118.
Biancari F, Myllylä M, Lepojärvi S, Kuttila K, Porela P, Laitio T, Ylitalo A, Jokinen V, Luokkala A, Airaksinen KE. Preoperative warfarin treatment and outcome of coronary artery bypass graft surgery. Ann Thorac Surg. 2010;89(4):1139–45.PubMedCrossRef
119.
Hata M, Akiyama K, Wakui S, Takasaka A, Sezai A, Shiono M. Does warfarin help prevent ischemic stroke in patients presenting with post coronary bypass paroxysmal atrial fibrillation? Ann Thorac Cardiovasc Surg. 2013;19(3):207–11.PubMedCrossRef
120.
Fremes SE, et al. Optimal antithrombotic therapy following aortocoronary bypass: a meta-analysis. Eur J Cardiothorac Surg. 1993;7:169–80.PubMedCrossRef
121.
Yamaguchi A, Kitamura N, Miki T, Tatebayashi T, Kawashima M, Otaki M, Tamura H. Comparative study of anticoagulant management after coronary artery bypass surgery—warfarin versus dipyridamole. Nihon Kyobu Geka Gakkai Zasshi. 1992;40(4):485–9.PubMed
122.
van der Meer J, Hillege HL, Kootstra GJ. Prevention of one-year vein-graft occlusion after aortocoronary-bypass surgery: a comparison of low-dose aspirin, low-dose aspirin plus dipyridamole, and oral anticoagulants. The CABADAS Research Group of the Interuniversity Cardiology Institute of The Netherlands. Lancet. 1993;342:257–64.PubMedCrossRef
123.
Gohlke H, Gohlke-Barwolf C, Sturzenhofecker P, et al. Improved graft patency with anticoagulant therapy after aortocoronary bypass surgery: a prospective, randomized study. Circulation. 1981;64(2 Pt 2):II22–7.PubMed
124.
Investigators The Post Coronary Artery Bypass Graft Trial. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary–artery bypass grafts. N Engl J Med. 1997;336:153–62.CrossRef
125.
Huynh T, Théroux P, Bogaty P, Nasmith J, Solymoss S. Aspirin, warfarin, or the combination for secondary prevention of coronary events in patients with acute coronary syndromes and prior coronary artery bypass surgery. Circulation. 2001;103(25):3069–74.PubMedCrossRef
126.
Smith PK, Goodnough LT, Levy JH, Poston RS, Short MA, Weerakkody GJ, Lenarz LA. Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis. J Am Coll Cardiol. 2012;60(5):388–96.PubMedPubMedCentralCrossRef
127.
Held C, Asenblad N, Bassand JP, Becker RC, Cannon CP, Claeys MJ, Harrington RA, Horrow J, Husted S, James SK, Mahaffey KW, Nicolau JC, Scirica BM, Storey RF, Vintila M, Ycas J, Wallentin L. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol. 2011;57(6):672–84.PubMedCrossRef
128.
Brilakis ES, Held C, Meier B, Cools F, Claeys MJ, Cornel JH, Aylward P, Lewis BS, Weaver D, Brandrup-Wognsen G, Stevens SR, Himmelmann A, Wallentin L, James SK. Effect of ticagrelor on the outcomes of patients with prior coronary artery bypass graft surgery: insights from the PLATelet inhibition and patient outcomes (PLATO) trial. Am Heart J. 2013;166(3):474–80.PubMedCrossRef
129.
Hansson EC, Jidéus L, Åberg B, Bjursten H, Dreifaldt M, Holmgren A, Ivert T, Nozohoor S, Barbu M, Svedjeholm R, Jeppsson A. Coronary artery bypass grafting-related bleeding complications in patients treated with ticagrelor or clopidogrel: a nationwide study. Eur Heart J. 2016;37(2):189–97.PubMedCrossRef
130.
Knatterud GL, Rosenberg Y, Campeau L, Geller NL, Hunninghake DB, Forman SA, Forrester JS, Gobel FL, Herd JA, Hickey A, Hoogwerf BJ, Terrin ML, White C. Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the Post Coronary Artery Bypass Graft Trial: Post CABG Investigators. Circulation. 2000;102:157–65.PubMedCrossRef
131.
Makuuchi H, Furuse A, Endo M, et al. Effect of pravastatin on progression of coronary atherosclerosis in patients after coronary artery bypass surgery. Circ J. 2005;69:636–43.PubMedCrossRef
132.
Kulik A, Voisine P, Mathieu P, Masters RG, Mesana TG, Le May MR, Ruel M. Statin therapy and saphenous vein graft disease after coronary bypass surgery: analysis from the CASCADE randomized trial. Ann Thorac Surg. 2011;92(4):1284–90.PubMedCrossRef
133.
Kang S, Liu Y, Liu XB. Effects of aggressive statin therapy on patients with coronary saphenous vein bypass grafts: a systematic review and meta-analysis of randomized, controlled trials. Clin Ther. 2013;35(8):1125–36.PubMedCrossRef
134.
Frick MH, Syvanne M, Nieminen MS, et al. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) study group. Circulation. 1997;96:2137–43.PubMedCrossRef
135.
Blankenhorn DH, Johnson RL, Nessim SA, Azen SP, Sanmarco ME, Selzer RH. The cholesterol lowering atherosclerosis study (CLAS): design, methods, and baseline results. Control Clin Trials. 1987;8:356–87.PubMedCrossRef
136.
Cashin-Hemphill L, Mack WJ, Pogoda JM, Sanmarco ME, Azen SP, Blankenhorn DH. Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up. JAMA. 1990;264:3013–7.PubMedCrossRef
137.
Azen SP, Mack WJ, Cashin-Hemphill L, et al. Progression of coronary artery disease predicts clinical coronary events. Long-term follow-up from the cholesterol lowering atherosclerosis study. Circulation. 1996;93:34–41.PubMedCrossRef
138.
139.
Veillard NR, Braunersreuther V, Arnaud C, et al. Simvastatin modulates chemokine and chemokine receptor expression by geranylgeranyl isoprenoid pathway in human endothelial cells and macrophages. Atherosclerosis. 2006;188:51–8.PubMedCrossRef
140.
Barakat A, Saad M, Abuzaid A, et al. Perioperative statin therapy for patients undergoing coronary artery bypass grafting. Ann Thorac Surg. 2016;101:818–25.PubMedCrossRef
141.
Hillis LD, Smith PK, Anderson JL, Bittl JA, Bridges CR, Byrne JG, Cigarroa JE, DiSesa VJ, Hiratzka LF, Hutter AM Jr, Jessen ME, Keeley EC, Lahey SJ, Lange RA, London MJ, Mack MJ, Patel MR, Puskas JD, Sabik JF, Selnes O, Shahian DM, Trost JC, Winniford MD, Jacobs AK, Anderson JL, Albert N, Creager MA, Ettinger SM, Guyton RA, Halperin JL, Hochman JS, Kushner FG, Ohman EM, Stevenson W, Yancy CW, American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2011 ACCF/AHA guideline for coronary artery bypass graft surgery: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Thorac Cardiovasc Surg. 2012;143(1):4–34.PubMedCrossRef
142.
Southerland KW, Frazier SB, Bowles DE, Milano CA, Kontos CD. Gene therapy for the prevention of vein graft disease. Transl Res. 2013;161(4):321–38.PubMedCrossRef
143.
Grube E, Felderhoff T, Fitzgerald P, et al. Late-breaking clinical trial abstracts. Circulation. 2001;104:1b–4b.CrossRef
144.
Alexander JH, Hafley G, Harrington RA, PREVENT IV Investigators, et al. Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. JAMA. 2005;294:2446–54.PubMedCrossRef
145.
Brilakis ES, Ty Wang, Rao SV, et al. Frequency and predictors of drug-eluting stent use in saphenous vein bypass graft percutaneous coronary interventions: a report from the American College of Cardiology National Cardiovascular Data CathPCI registry. JACC Cardiovasc Interv. 2010;3(10):1068–73.PubMedCrossRef
146.
Marmagkiolis K, Grines C, Bilodeau L. Current percutaneous treatment strategies for saphenous vein graft disease. Catheter Cardiovasc Interv. 2013;82(3):406–13.PubMedCrossRef
147.
Savage MP, Douglas JS Jr, Fischman DL, et al. Stent placement compared with balloon angioplasty for obstructed coronary bypass grafts. Saphenous Vein De Novo Trial Investigators. N Engl J Med. 1997;337:740–7.PubMedCrossRef
148.
Hanekamp CE, Koolen JJ, Den Heijer P, Schalij MJ, Piek JJ, Bar FW, De Scheerder I, Bonnier HJ, Pijls NH. Randomized study to compare balloon angioplasty and elective stent implantation in venous bypass grafts: the Venestent study. Catheter Cardiovasc Interv. 2003;60:452–7.PubMedCrossRef
149.
Vermeersch P, Agostoni P, Verheye S, et al. Randomized double-blind comparison of sirolimus-eluting stent versus bare-metal stent implantation in diseased saphenous vein grafts: six-month angiographic, intravascular ultrasound, and clinical follow-up of the RRISC Trial. J Am Coll Cardiol. 2006;48:2423–31.PubMedCrossRef
150.
Brilakis ES, Lichtenwalter C, de Lemos JA, Roesle M, Obel O, Haagen D, Saeed B, Gadiparthi C, Bissett JK, Sachdeva R, Voudris VV, Karyofillis P, Kar B, Rossen J, Fasseas P, Berger P, Banerjee S. A randomized controlled trial of a paclitaxel-eluting stent versus a similar bare-metal stent in saphenous vein graft lesions the SOS (stenting of saphenous vein grafts) trial. J Am Coll Cardiol. 2009;53(11):919–28.PubMedCrossRef
151.
Mehilli J, Pache J, Abdel-Wahab M, et al. Drug-eluting versus bare-metal stents in saphenous vein graft lesions (ISAR-CABG): a randomised controlled superiority trial. Lancet. 2011;378:1071–8.PubMedCrossRef
152.
Meier P, Brilakis ES, Corti R, Knapp G, Shishehbor MH, Gurm HS. Drug-eluting versus bare-metal stent for treatment of saphenous vein grafts: a meta-analysis. PLoS One. 2010;5:e11040.PubMedPubMedCentralCrossRef
153.
Testa L, Agostoni P, Vermeersch P, et al. Drug eluting stents versus bare metal stents in the treatment of saphenous vein graft disease: a systematic review and meta-analysis. EuroIntervention. 2010;6:527–36.PubMedCrossRef
154.
Lee MS, Hu PP, Aragon J, et al. Comparison of sirolimus-eluting stents with paclitaxel-eluting stents in saphenous vein graft intervention (from a multicenter Southern California Registry). Am J Cardiol. 2010;106:337–41.PubMedCrossRef
155.
Hougaard M, Thayssen P, Kaltoft A, Tilsted HH, Maeng M, Lassen JF, Thuesen L, Okkels Jensen L. Long-term outcome following percutaneous coronary intervention with drug-eluting stents compared with bare-metal stents in saphenous vein graft lesions: from Western Denmark Heart Registry. Catheter Cardiovasc Interv. 2014;83(7):1035–42.PubMedCrossRef
156.
Kitabata H, Loh JP, Pendyala LK, Badr S, Dvir D, Barbash IM, Minha S, Torguson R, Chen F, Satler LF, Suddath WO, Kent KM, Pichard AD, Waksman R. Two-year follow-up of outcomes of second-generation everolimus-eluting stents versus first-generation drug-eluting stents for stenosis of saphenous vein grafts used as aortocoronary conduits. Am J Cardiol. 2013;112(1):61–7.PubMedCrossRef
157.
Pokala NR, Menon RV, Patel SM, Christopoulos G, Christakopoulos GE, Kotsia AP, Rangan BV, Roesle M, Abdullah S, Grodin J, Kumbhani DJ, Hastings J, Banerjee S, Brilakis ES. Long-term outcomes with first- vs. second-generation drug-eluting stents in saphenous vein graft lesions. Catheter Cardiovasc Interv. 2016;87(1):34–40.PubMedCrossRef
158.
Costopoulos C, Latib A, Naganuma T, Sticchi A, Chieffo A, Figini F, Carlino M, Montorfano M, Naim C, Kawaguchi M, Giannini F, Colombo A. Comparison of first- and second-generation drug-eluting stents in saphenous vein grafts used as aorto-coronary conduits. Am J Cardiol. 2013;112(3):318–22.PubMedCrossRef
159.
Yaku H, Doi K. Redo coronary artery bypass grafting. Gen Thorac Cardiovasc Surg. 2014;62(8):453–60.PubMedCrossRef
160.
Stamou SC, Pfister AJ, Dullum MK, et al. Late outcome of reoperative coronary re-vascularization on the beating heart. Heart Surg Forum. 2001;4:69–73.PubMed
161.
Christenson JT, Schmuziger M, Simonet F. Reoperative coronary artery bypass procedures: risk factors for early mortality and late survival. Eur J Cardiothorac Surg. 1997;11:129–33.PubMedCrossRef
162.
Labinaz M, Kilaru R, Pieper K, et al. Outcomes of patients with acute coronary syndromes and prior coronary artery bypass grafting: results from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial. Circulation. 2002;105:322–7.PubMedCrossRef
163.
Labinaz M, Sketch MH Jr, Ellis SG, et al. Outcome of acute ST-segment elevation myocardial infarction in patients with prior coronary artery bypass surgery receiving thrombolytic therapy. Am Heart J. 2001;141:469–77.PubMedCrossRef
164.
Nikolsky E, McLaurin BT, Cox DA, et al. Outcomes of patients with prior coronary artery bypass grafting and acute coronary syndromes: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. JACC Cardiovasc Interv. 2012;5:919–26.PubMedCrossRef
165.
Gurfinkel EP, de la Perez HR, Brito VM, et al. Invasive vs non-invasive treatment in acute coronary syndromes and prior bypass surgery. Int J Cardiol. 2007;119:65–72.PubMedCrossRef
166.
Held C, Tornvall P, Stenestrand U. Effects of revascularization within 14 days of hospital admission due to acute coronary syndrome on 1-year mortality in patients with previous coronary artery bypass graft surgery. Eur Heart J. 2007;28:316–25.PubMedCrossRef
167.
Stephan WJ, O’Keefe JH Jr, Piehler JM, et al. Coronary angioplasty versus repeat coronary artery bypass grafting for patients with previous bypass surgery. J Am Coll Cardiol. 1996;28:1140–6.PubMedCrossRef
168.
Morrison DA, Sethi G, Sacks J, Henderson W, Grover F, Sedlis S, Esposito R, Ramanathan K, Weiman D, Saucedo J, Antakli T, Pramesh V, Pett S, Vernon S, Birjiniuk V, Welt F, Krucoff M, Wolfe W, Lucke JC, Mediratta S, Booth D, Barbiere C, Lewis D. Percutaneous coronary intervention versus coronary artery bypass graft surgery for patients with medically refractory myocardial ischemia and risk factors for adverse outcomes with bypass: a multicenter randomized trial. Investigators of the Department of Veterans Affairs Cooperative Study #385, the Angina With Extremely Serious Operative Mortality Evaluation (AWESOME). J Am Coll Cardiol. 2001;38(143–9):8.
169.
Morrison DA, Sethi G, Sacks J, Henderson WG, Grover F, Sedlis S, Esposito R. Percutaneous coronary intervention versus repeat bypass surgery for patients with medically refractory myocardial ischemia: AWESOME randomized trial and registry experience with post-CABG patients. J Am Coll Cardiol. 2002;40:1951–4.PubMedCrossRef
170.
Brener SJ, Lytle BW, Casserly IP, Ellis SG, Topol EJ, Lauer MS. Predictors of revascularization method and long-term outcome of percutaneous coronary intervention or repeat coronary bypass surgery in patients with multivessel coronary disease and previous coronary bypass surgery. Eur Heart J. 2006;27:413–8.PubMedCrossRef
171.
Cole JH, Jones EL, Craver JM, et al. Outcomes of repeat revascularization in diabetic patients with prior coronary surgery. J Am Coll Cardiol. 2002;40:1968–75.PubMedCrossRef
172.
Harskamp RE, Beijk MA, Damman P, et al. Clinical outcome after surgical or percutaneous revascularization in coronary bypass graft failure. J Cardiovasc Med. 2013;14(6):438–45.CrossRef
173.
Byrne J, Leacche M, Vaughan D, et al. Hybrid cardiovascular procedures. JACC Card Int. 2008;1:459–68.CrossRef
174.
Gilard M, Bezon E, Cornily JC, et al. Same-day combined percutaneous coronary intervention and coronary artery surgery. Cardiology. 2007;108:363–7.PubMedCrossRef
175.
Holzhey DM, Jacobs S, Mochalski M, et al. Minimally invasive hybrid coronary artery revascularization. Ann Thorac Surg. 2008;86:1856–60.PubMedCrossRef
Metadata
Title
Management and Prevention of Saphenous Vein Graft Failure: A Review
Authors
Peter McKavanagh
Bobby Yanagawa
George Zawadowski
Asim Cheema
Publication date
01-12-2017
Publisher
Springer Healthcare
Published in
Cardiology and Therapy / Issue 2/2017
Print ISSN: 2193-8261
Electronic ISSN: 2193-6544
DOI
https://doi.org/10.1007/s40119-017-0094-6

Other articles of this Issue 2/2017

Cardiology and Therapy 2/2017 Go to the issue

Original Research

Analytical Management of Patients Undergoing Oral Anticoagulant Therapy Could Have a Strong Impact on Clinical Outcomes: A Follow-up Study

Original Research

Elevated Circulating PCSK9 Concentrations Predict Subclinical Atherosclerotic Changes in Low Risk Obese and Non-Obese Patients

Review

Leadless Pacing: Current State and Future Direction

Original Research

Medical Therapy and Recurrent Ischemic Events in High Risk Patients Surviving their Myocardial Infarction for at Least 12 Months: Comparison of Patients with ST Elevation Versus Non-ST Elevation Myocardial Infarction

Review

Exosomes in Cardiovascular Medicine

Original Research

Treatment of Stable Angina with a New Fixed-Dose Combination of Ivabradine and Metoprolol: Effectiveness and Tolerability in Routine Clinical Practice

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits